Cargando…
Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease
Increasing evidence shows that metabolic abnormalities in body fluids are distinguishing features of the pathophysiology of Parkinson’s disease. However, a non-invasive approach has not been established in the earliest or pre-symptomatic phases. Here, we report comprehensive double-cohort analyses o...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544708/ https://www.ncbi.nlm.nih.gov/pubmed/28779141 http://dx.doi.org/10.1038/s41598-017-06767-y |
_version_ | 1783255288139218944 |
---|---|
author | Saiki, Shinji Hatano, Taku Fujimaki, Motoki Ishikawa, Kei-Ichi Mori, Akio Oji, Yutaka Okuzumi, Ayami Fukuhara, Takeshi Koinuma, Takahiro Imamichi, Yoko Nagumo, Miho Furuya, Norihiko Nojiri, Shuko Amo, Taku Yamashiro, Kazuo Hattori, Nobutaka |
author_facet | Saiki, Shinji Hatano, Taku Fujimaki, Motoki Ishikawa, Kei-Ichi Mori, Akio Oji, Yutaka Okuzumi, Ayami Fukuhara, Takeshi Koinuma, Takahiro Imamichi, Yoko Nagumo, Miho Furuya, Norihiko Nojiri, Shuko Amo, Taku Yamashiro, Kazuo Hattori, Nobutaka |
author_sort | Saiki, Shinji |
collection | PubMed |
description | Increasing evidence shows that metabolic abnormalities in body fluids are distinguishing features of the pathophysiology of Parkinson’s disease. However, a non-invasive approach has not been established in the earliest or pre-symptomatic phases. Here, we report comprehensive double-cohort analyses of the metabolome using capillary electrophoresis/liquid chromatography mass-spectrometry. The plasma analyses identified 18 Parkinson’s disease-specific metabolites and revealed decreased levels of seven long-chain acylcarnitines in two Parkinson’s disease cohorts (n = 109, 145) compared with controls (n = 32, 45), respectively. Furthermore, statistically significant decreases in five long-chain acylcarnitines were detected in Hoehn and Yahr stage I. Likewise, decreased levels of acylcarnitine(16:0), a decreased ratio of acylcarnitine(16:0) to fatty acid(16:0), and an increased index of carnitine palmitoyltransferase 1 were identified in Hoehn and Yahr stage I of both cohorts, suggesting of initial β-oxidation suppression. Receiver operating characteristic curves produced using 12–14 long-chain acylcarnitines provided a large area of under the curve, high specificity and moderate sensitivity for diagnosing Parkinson’s disease. Our data demonstrate that a primary decrement of mitochondrial β-oxidation and that 12–14 long-chain acylcarnitines decreases would be promising diagnostic biomarkers for Parkinson’s disease. |
format | Online Article Text |
id | pubmed-5544708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55447082017-08-07 Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease Saiki, Shinji Hatano, Taku Fujimaki, Motoki Ishikawa, Kei-Ichi Mori, Akio Oji, Yutaka Okuzumi, Ayami Fukuhara, Takeshi Koinuma, Takahiro Imamichi, Yoko Nagumo, Miho Furuya, Norihiko Nojiri, Shuko Amo, Taku Yamashiro, Kazuo Hattori, Nobutaka Sci Rep Article Increasing evidence shows that metabolic abnormalities in body fluids are distinguishing features of the pathophysiology of Parkinson’s disease. However, a non-invasive approach has not been established in the earliest or pre-symptomatic phases. Here, we report comprehensive double-cohort analyses of the metabolome using capillary electrophoresis/liquid chromatography mass-spectrometry. The plasma analyses identified 18 Parkinson’s disease-specific metabolites and revealed decreased levels of seven long-chain acylcarnitines in two Parkinson’s disease cohorts (n = 109, 145) compared with controls (n = 32, 45), respectively. Furthermore, statistically significant decreases in five long-chain acylcarnitines were detected in Hoehn and Yahr stage I. Likewise, decreased levels of acylcarnitine(16:0), a decreased ratio of acylcarnitine(16:0) to fatty acid(16:0), and an increased index of carnitine palmitoyltransferase 1 were identified in Hoehn and Yahr stage I of both cohorts, suggesting of initial β-oxidation suppression. Receiver operating characteristic curves produced using 12–14 long-chain acylcarnitines provided a large area of under the curve, high specificity and moderate sensitivity for diagnosing Parkinson’s disease. Our data demonstrate that a primary decrement of mitochondrial β-oxidation and that 12–14 long-chain acylcarnitines decreases would be promising diagnostic biomarkers for Parkinson’s disease. Nature Publishing Group UK 2017-08-04 /pmc/articles/PMC5544708/ /pubmed/28779141 http://dx.doi.org/10.1038/s41598-017-06767-y Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Saiki, Shinji Hatano, Taku Fujimaki, Motoki Ishikawa, Kei-Ichi Mori, Akio Oji, Yutaka Okuzumi, Ayami Fukuhara, Takeshi Koinuma, Takahiro Imamichi, Yoko Nagumo, Miho Furuya, Norihiko Nojiri, Shuko Amo, Taku Yamashiro, Kazuo Hattori, Nobutaka Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title_full | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title_fullStr | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title_full_unstemmed | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title_short | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease |
title_sort | decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544708/ https://www.ncbi.nlm.nih.gov/pubmed/28779141 http://dx.doi.org/10.1038/s41598-017-06767-y |
work_keys_str_mv | AT saikishinji decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT hatanotaku decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT fujimakimotoki decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT ishikawakeiichi decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT moriakio decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT ojiyutaka decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT okuzumiayami decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT fukuharatakeshi decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT koinumatakahiro decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT imamichiyoko decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT nagumomiho decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT furuyanorihiko decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT nojirishuko decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT amotaku decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT yamashirokazuo decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease AT hattorinobutaka decreasedlongchainacylcarnitinesfrominsufficientboxidationaspotentialearlydiagnosticmarkersforparkinsonsdisease |